文献速递胸部肿瘤放疗放疗物理与技术

肺癌放疗相关淋巴细胞减少症的风险与影响:系统综述与荟萃分析

Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis.
PubMed 文献 · Radiother Oncol · 2021-02-10

结果显示重度淋巴细胞减少症(绝对淋巴细胞计数<500)总体平均发生率为64.24%,且与死亡风险(合并HR 1.59,95%CI 1.40-1.81,P<0.001)和进展风险(合并HR 2.1,95%CI 1.57-2.81,P<0.001)增加相关。剂量学参数如大体肿瘤体积、肺V5和心脏V5可预测淋巴细胞减少症。

要点

  • 重度淋巴细胞减少症总体平均发生率为64.24%。
  • 重度淋巴细胞减少症与死亡风险增加相关(合并HR 1.59,95%CI 1.40-1.81)。
  • 重度淋巴细胞减少症与进展风险增加相关(合并HR 2.1,95%CI 1.57-2.81)。

核心结论

  • 放疗相关淋巴细胞减少症与肺癌患者进展和死亡风险增加相关。
  • 尽量减少肺和心脏剂量,尤其对合并其他危险因素的患者,可减少淋巴细胞减少症并可能改善治疗结局。

研究设计与样本

  • 使用Review Manager 5.4.1软件进行荟萃分析。

主要发现

  • 重度淋巴细胞减少症(绝对淋巴细胞计数<500)总体平均发生率为64.24%。
  • 与无重度淋巴细胞减少症患者相比,重度淋巴细胞减少症患者死亡风险增加,合并HR为1.59(95%CI:1.40,1.81,I2=17%,P<0.001)。
  • 与无重度淋巴细胞减少症患者相比,重度淋巴细胞减少症患者进展风险增加,合并HR为2.1(95%CI:1.57,2.81,I2=59%,P<0.001)。
  • 剂量学参数包括大体肿瘤体积、肺V5和心脏V5可预测淋巴细胞减少症。
  • 高龄、较低基线淋巴细胞计数、较高分期和较大肿瘤体积是其他危险因素。

关键数值与推荐

  • 重度淋巴细胞减少症定义为绝对淋巴细胞计数<500。
  • 预测淋巴细胞估计辐射剂量的模型是治疗结局的良好替代指标。

临床怎么用

  • 在肺癌放疗计划中应尽量减少肺和心脏剂量,以降低淋巴细胞减少症风险。
  • 对合并高龄、低基线淋巴细胞计数、高分期或大肿瘤体积等危险因素的患者,尤需关注淋巴细胞减少症的预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the modern advances in treatment techniques, the survival of locally advanced lung cancer patients continues to remain poor. Circulating lymphocytes have an important role to play in local immune response to RT as well as immune checkpoint inhibitors, and radiation related lymphopenia has been associated with inferior survival in various tumors. METHODS: We undertook this systematic review and meta-analysis to evaluate the literature on risk and impact of lymphopenia in thoracic tumors. A systematic methodology search of the PubMed, Embase and Cochrane library was performed and eligible studies selected based on pre-defined inclusion and exclusion criteria. Review Manager Version 5.4.1 was used for the meta-analysis. RESULTS: Fourteen studies were included in the final systematic review and 10 in the quantitative analysis. Overall mean incidence of severe lymphopenia (absolute lymphocyte count < 500) was 64.24%. The patients with severe lymphopenia were at increased risk of death with a pooled HR of 1.59 (95% CI: 1.40, 1.81, I2 = 17%, P < 0.001) and progression with a pooled HR of 2.1 (95% CI: 1.57, 2.81, I2 = 59%, P < 0.001) compared to patients with no severe lymphopenia. Dosimetric parameters including gross tumor volume, lung V5 and heart V5 were predictive of lymphopenia, while advanced age, lower baseline lymphocyte counts, higher stage and large tumor size were other risk factors. Models predicting estimated radiation dose to lymphocytes were a good surrogate for treatment outcomes. CONCLUSION: Radiation related lymphopenia is associated with increased hazard of progression and death in lung cancer. Minimizing the lung and heart dose, especially in patients with concurrent other risk factors can reduce lymphopenia and potentially improve treatment outcomes in these patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Upadhyay R, Venkatesulu BP, Giridhar P, et al. Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis. Radiother Oncol. 2021. PMID: 33577865. doi:10.1016/j.radonc.2021.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。